Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Vivani Medical Inc. (VANI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: VANI (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $4
1 Year Target Price $4
| 0 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 56.76% | Avg. Invested days 36 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 78.20M USD | Price to earnings Ratio - | 1Y Target Price 4 |
Price to earnings Ratio - | 1Y Target Price 4 | ||
Volume (30-day avg) 2 | Beta 3.33 | 52 Weeks Range 0.91 - 1.50 | Updated Date 06/29/2025 |
52 Weeks Range 0.91 - 1.50 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.42 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -35.03% | Return on Equity (TTM) -117.76% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 83541512 | Price to Sales(TTM) - |
Enterprise Value 83541512 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -3.93 | Shares Outstanding 59243900 | Shares Floating 30972712 |
Shares Outstanding 59243900 | Shares Floating 30972712 | ||
Percent Insiders 49.04 | Percent Institutions 8.03 |
Analyst Ratings
Rating 2 | Target Price 4 | Buy 2 | Strong Buy - |
Buy 2 | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Vivani Medical Inc.
Company Overview
History and Background
Vivani Medical Inc., formerly Second Sight Medical Products, Inc., is a biopharmaceutical company focused on the development of long-term, miniaturized drug implants. The company has evolved from developing retinal prostheses to developing sustained drug delivery systems.
Core Business Areas
- Nefeli Biosciences: Nefeli Biosciences is a wholly-owned subsidiary of Vivani Medical focused on developing innovative treatments for chronic diseases.
- Drug Delivery Implant Technology: Development of proprietary miniaturized, long-term drug delivery implant technology for chronic diseases, aiming for continuous drug release and improved patient compliance.
Leadership and Structure
The leadership team consists of key executives in research and development, clinical operations, and business development. The company structure is typical of a publicly traded biotechnology company, with a board of directors overseeing executive management.
Top Products and Market Share
Key Offerings
- Nefeliu2122: A miniaturized, long-term drug delivery implant being developed for the treatment of chronic weight management. It is in clinical trials. Competitors include Novo Nordisk (NVO) and Eli Lilly (LLY) with injectables like Wegovy and Mounjaro.
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive, with numerous companies developing novel therapies and drug delivery systems. The market for obesity and diabetes treatments is expanding.
Positioning
Vivani Medical aims to compete by offering a long-term, implantable solution for chronic diseases, potentially improving patient adherence and outcomes compared to existing therapies.
Total Addressable Market (TAM)
The global obesity market is estimated to be in the tens of billions of dollars annually. Vivani Medical's positioning within this TAM depends on the successful development and commercialization of Nefeliu2122.
Upturn SWOT Analysis
Strengths
- Proprietary drug delivery implant technology
- Focus on long-term, sustained drug release
- Potential for improved patient compliance
- Experienced management team
Weaknesses
- Limited product portfolio
- Dependence on successful clinical trials
- High research and development costs
- Relatively small company size compared to competitors
Opportunities
- Expanding market for obesity and diabetes treatments
- Partnerships with larger pharmaceutical companies
- Further development of drug delivery platform for other indications
- Potential for regulatory approvals and market exclusivity
Threats
- Competition from established pharmaceutical companies
- Clinical trial failures
- Regulatory hurdles
- Changes in reimbursement policies
- Technological advancements from competitors
Competitors and Market Share
Key Competitors
- NVO
- LLY
Competitive Landscape
Vivani Medical faces intense competition from established pharmaceutical companies with greater resources and broader product portfolios. Its success depends on demonstrating the superiority of its drug delivery platform.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by the company's shift from retinal prostheses to drug delivery implants. Growth is dependent on securing funding, completing clinical trials, and achieving regulatory approvals.
Future Projections: Future growth projections depend on successful clinical trials and regulatory approvals for Nefeliu2122 and other potential products.
Recent Initiatives: Recent initiatives include advancing clinical trials for Nefeliu2122 and exploring partnerships for further development and commercialization.
Summary
Vivani Medical is a development-stage biopharmaceutical company focused on innovative drug delivery technology. Its strengths lie in its novel implantable device, but it faces significant challenges including clinical trial risks and competition from larger companies. Successful clinical trials and strategic partnerships will be critical for its future growth. The company needs to focus on securing funding to sustain its operations and to mitigate threats from established competitors. The potential of the device is considerable, but the risk is also high.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Industry reports
- Analyst estimates
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market share data is based on estimates and may not be precise. Financial figures are demonstrative and should be checked with official filings.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Vivani Medical Inc.
Exchange NASDAQ | Headquaters Alameda, CA, United States | ||
IPO Launch date 2014-11-19 | Co-Founder, CEO & Director Dr. Adam Mendelsohn Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 37 | Website https://www.vivani.com |
Full time employees 37 | Website https://www.vivani.com | ||
Vivani Medical, Inc., a clinical-stage biopharmaceutical company, engages in the development of miniaturized and subdermal drug implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates in the treatment of chronic disease and medication non-adherence. Its pipeline includes NPM-115, a high-dose exenatide implant candidate is in clinical stage development for the treatment of chronic weight management in patients with obesity or overweight; NPM-119, an exenatide implant candidate is in preclinical stage development for the treatment of patients with type 2 diabetes; NPM-139, a miniature and subdermal GLP-1 implant in development for chronic weight management; and OKV-119, an exenatide implant for metabolic diseases in cats. The company is headquartered in Alameda, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.